Gastrointestinal Cancer

Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.

Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.

The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

The primary end point of progression-free survival was met with retifanlimab to carboplatin and paclitaxel in patients with metastatic SCAC.

The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.

Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.

Developers anticipate launching a first-in-human phase 1 study assessing ziftomenib/imatinib for those with advanced GISTs in early 2025.

Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.

Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.

Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.

The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.

The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.

The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.

The FDA has set a Prescription Drug User Fee Act date of November 29, 2024, for zanidatamab in this biliary tract cancer population.

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.

Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.